$ASND · Ascendis Pharma A/S
Ascendis Pharma reported Q3 2026 results: total revenue €370M (+89% Y/Y from €214M), product revenue €366M, operating profit €125M (34% margin), and net profit €74M (€1.08 diluted EPS) versus a €61M net loss a year earlier. YORVIPATH led with €291M (+103% Y/Y), SKYTROFA €59M, and YUVIWEL €16M. Cash and equivalents rose to €964M from €616M at year-end 2025, and the company expects full-year 2026 operating cash flow of at least €600M.
- Q3 2026 total revenue €370M, up 89% Y/Y from €214M.
- YORVIPATH revenue €291M, up 103% Y/Y; now in 40+ countries.
- Net profit €74M (€1.08 diluted EPS) vs €61M net loss a year ago.
- Cash and equivalents €964M at Sept 30, 2026, up from €616M at year-end 2025.
- Repurchased 1,998,999 shares for $459M year-to-date through Nov 11, 2026.
Extended-hours last trade $267.06, +3.00% vs regular close, signaling a positive after-hours reaction to the strong quarter and swing to profitability.
Ascendis delivered its first sustained profitability inflection, with YORVIPATH sales more than doubling and a near-term EU catalyst for TransCon CNP.
Ascendis' three approved rare endocrine therapies (YORVIPATH, SKYTROFA, YUVIWEL) are scaling toward durable commercial growth, with YORVIPATH now generating over €290M quarterly.
Regulatory and clinical risks include possible delays or failure to obtain EU approval for TransCon CNP, and pivotal infant achondroplasia data not expected until Q3 2027. Commercial risks include payer coverage, pricing, and reimbursement challenges across new country launches.